Company Summary
Neuro-Bio is a development-stage biopharmaceutical company focused on developing novel, effective therapeutics for neurodegenerative disorders including Alzheimer’s, Parkinson’s and Motor Neuron Diseases.
Year Founded: 2013
Key Executives:
Baroness Professor Susan Greenfield, CEO, Founder & Board Member
Latest News
29May
Researchers examine evidence for a novel neuronal mechanism driving Alzheimer’s disease
Researchers at Neuro-Bio Ltd in collaboration with an international team of clinicians and neuroscientists have published...
Read more
04Mar
Aptamer and Neuro-Bio Enter the Second Phase of Alzheimer’s Test Development
Aptamer Group plc, the developer of novel Optimer binders, announces the second phase of its on-going partnership with Neuro-Bio,...
Read more
14Jun
Aptamer Group and Neuro-Bio Partner to Develop an Alzheimer’s Disease Diagnostic Test
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences...
Read more
06Jun
Breakthrough Alzheimer’s Cure Aims for Human Trials – Neuro-Bio
Neuro-Bio is ready to move to human trials using a radical approach that targets neurodegeneration long...
Read more
02Apr
Oxford Scientists Hail Major Breakthrough which Could Provide Relief to 900,000 Britons with Dementia – Neuro-Bio
British scientists believe they may have discovered the first effective treatment for dementia. Researchers at Neuro-Bio say...
Read more
10Jun
Careers in Discovery Podcast with Neuro-Bio CEO Baroness Susan Greenfield
Baroness Susan Greenfield is, among other things, a scientist, author, broadcaster, member of the House of...
Read more
22Mar
Kairos Ventures Invests in Neuro-Bio
We are pleased to announce that Neuro-Bio is the latest company to join the Kairos portfolio,...
Read more